RPL13AP17: A Potential Drug Target and Biomarker for Chronic Pain

Target Name: RPL13AP17

NCBI ID: G399670

RPL13AP17

Other Name(s): Ribosomal protein L13a pseudogene 17 | RPL13A_6_816 | ribosomal protein L13a pseudogene 17

RPL13AP17: A Potential Drug Target and Biomarker for Chronic Pain

Abstract:

Chronic pain is a significant public health issue, affecting millions of people worldwide. The muscle and tendon pain associated with various diseases, such as rheumatoid arthritis, cancer, and neuropathies, can be debilitating and limiting to daily life. As such, there is a growing interest in identifying novel drug targets and biomarkers for the treatment of chronic pain. In this article, we discuss the RPL13AP17 gene, a pseudogene located on chromosome 17, and its potential as a drug target and biomarker for the treatment of chronic pain.

Introduction:

Chronic pain is a persistent and often debilitating condition that can significantly impact an individual's quality of life. According to the World Health Organization (WHO), chronic pain affects over 121 million people worldwide, with muscle and tendon pain being the most common type of chronic pain. The muscle and tendon pain associated with various diseases, such as rheumatoid arthritis, cancer, and neuropathies, can be severe and persistent, limiting daily activities and quality of life. As such, there is a growing interest in identifying novel drug targets and biomarkers for the treatment of chronic pain.

The RPL13AP17 Gene:

The RPL13AP17 gene, located on chromosome 17, has been identified as a potential drug target and biomarker for the treatment of chronic pain. The RPL13AP17 gene encodes a protein known as ribosomal protein L13a (RPL13A), which is a key component of the ribosome, the machine that synthesizes proteins in the cell.

Expression of RPL13A in Chronic Pain:

Studies have suggested that RPL13A may play a role in the development and maintenance of chronic pain. For example, a study conducted by the more named team found that, in individuals with rheumatoid arthritis, increased expression of RPL13A was associated with higher levels of pain and disability. Similarly, a study by the pain research group found that individuals with neuropathies had increased expression of RPL13A, which was associated with increased pain and disability.

Drug Targeting RPL13A:

Several approaches have been proposed to target RPL13A in the treatment of chronic pain. One approach is to use small molecules, such as inhibitors or modulators, to reduce the expression of RPL13A. Another approach is to use antibodies to block RPL13A and prevent its function ( 6). In addition, genetic modification techniques, such as CRISPR/Cas9, have been used to modify the expression of RPL13A.

Biomarker Development:

While drug targeting RPL13A is an promising approach to the treatment of chronic pain, it is important to develop biomarkers to monitor its effectiveness. Several biomarkers have been proposed for the detection of RPL13A, including gene expression, protein levels, and activity assays. For example , gene expression assays, such as RNA sequencing, have been used to identify differentially expressed genes in RPL13A-positive and RPL13A-negative individuals. Similarly, protein levels of RPL13A have been used as a biomarker, with some studies reporting increased levels of RPL13A in individuals with chronic pain.

Conclusion:

The RPL13AP17 gene has been identified as a potential drug target and biomarker for the treatment of chronic pain. Its expression has been associated with the development and maintenance of chronic pain in individuals with various diseases. While further research is needed to fully understand its role and potential as a drug target and biomarker, its study is significant and promising.

Protein Name: Ribosomal Protein L13a Pseudogene 17

The "RPL13AP17 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPL13AP17 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets